A Randomised, Double Blind (Sponsor Unblinded), Placebo-controlled, First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Oral Doses and the Food Effect of GSK2556286 in Healthy Adult Participants
Latest Information Update: 20 May 2025
At a glance
- Drugs GSK 2556286 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 14 Nov 2023 Planned End Date changed from 15 Dec 2023 to 4 Jul 2024.
- 14 Nov 2023 Planned primary completion date changed from 15 Dec 2023 to 4 Jul 2024.
- 22 Jan 2023 Planned End Date changed from 30 Jun 2023 to 15 Dec 2023.